Microbiology Laboratory Data Integrity: What the Jaloma Warning Letter Teaches QC Labs

In December 2025, FDA investigators spent five days inside a large over the counter drug plant in Guadalajara, Mexico. What they found in the microbiology laboratory was not a single bad result. It was a pattern. A microbiologist had recorded routine sampling that was never actually performed. Colony counts were read and recorded after shorter incubation than the laboratory's own procedure demanded. By May 2026, Laboratorios Jaloma had an FDA warning letter, its products sat on an import alert, and the agency had called the problem a critical breakdown in laboratory controls.

Microbiology laboratory data integrity is where many inspections are won or lost, and it is one of the hardest areas to talk your way through once an investigator starts pulling plates, incubator logs and audit trails. The Jaloma case is part of a wider pattern of FDA data integrity warning letters. This article explains what the letter found, how inspectors test micro data in practice, and the controls that make your microbial results defensible. The lessons apply to any Canadian pharmaceutical, natural health product or contract testing operation that releases product on the strength of a microbiology result.

Executive Summary

Microbiology data integrity is not only a documentation exercise. It protects patients from contaminated product, and it protects your company from import alerts, recalls and lost market access. The sections below turn the Jaloma findings into practical controls your quality unit can defend.

What Microbiology Laboratory Data Integrity Means

Microbiology laboratory data integrity means that every microbial result is attributable to a real analyst, recorded as the work happens, based on a validated method, and traceable from sample receipt to final report. In plain terms, the data must reflect what actually happened at the bench. FDA, Health Canada and the EMA all expect laboratory records to be complete, accurate and original, so that a result cannot be invented, edited or deleted without a clear and reviewable trail.

Regulators describe these expectations with the ALCOA and ALCOA plus principles. They are not abstract ideals. Each one maps to a specific control you can inspect in a microbiology laboratory.

Principle	What it means in the microbiology laboratory
Attributable	Every count, read and sample is linked to the analyst who did it, through unique logins and signatures.
Legible	Records are permanent and readable, with no obscured or overwritten entries.
Contemporaneous	Results are recorded at the time of the read, not transcribed later from memory or scrap paper.
Original	The first record, such as the plate read or the instrument file, is retained, not a rewritten copy.
Accurate	Counts, dilutions and calculations are correct and match the raw data.
Complete	All data is kept, including failing and repeat results, with nothing discarded.
Consistent	Entries are in the expected sequence, with accurate dates and times.
Enduring and Available	Records are stored, backed up and retrievable for the full retention period.

What the Jaloma Warning Letter Actually Found

FDA inspected Laboratorios Jaloma from 15 to 19 December 2025 and issued a warning letter dated 22 May 2026 (reference 320-26-78). The agency concluded the firm's OTC drug products were adulterated under section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act, and it had already placed the site on Import Alert 66-40 in April 2026. The letter cites four current good manufacturing practice failures, and together they describe a microbiology laboratory whose data could not be relied on.

CGMP citation	What FDA found	Control that prevents it
21 CFR 211.194(a) Laboratory records	A microbiologist recorded sampling that was never performed, and colony counts were read after less incubation than the procedure required.	Contemporaneous recording at the bench, second person verification, and timestamped reads tied to the method.
21 CFR 211.160(b) Laboratory controls	Alternative microbial methods were not validated against compendial methods, the scope omitted anaerobic bacteria and total yeasts and molds, and incubation times did not align with USP general chapter 61.	Validate every method, map the scope to the compendial requirement, and justify each deviation in writing.
21 CFR 211.68(b) Computer controls	The gas chromatography system was not qualified, software was not validated, audit trails were disabled, file dates were inaccurate, data files were missing, and nothing was backed up.	Qualify systems, enable and review audit trails, control backups, and enforce unique access.
21 CFR 211.22 Quality control unit	The quality unit lacked adequate oversight and authority over manufacturing and laboratory operations.	An independent quality unit with authority to reject data and halt product release.

Read in sequence, the findings tell a familiar story. A method that was never properly validated produces results that are hard to defend. Records written to match expectations rather than observations hide the gaps. A computer system without audit trails or backups means no one can reconstruct what really happened. And a quality unit without authority never stops any of it. FDA asked the firm for a comprehensive, independent review of all laboratory data and a gap analysis of its data integrity controls, pointing to its guidance on Data Integrity and Compliance With Drug CGMP. If you want a ready structure for that kind of review, our data integrity checklist from the Curia warning letter is a useful starting point.

The Micro Lab Shortcuts Inspectors Look For

Investigators rarely find a signed confession. They find small shortcuts that, once pulled on, unravel into a data integrity finding. In the microbiology laboratory, the highest risk shortcuts involve incubation timing, plate reading, sampling that is recorded but not performed, and missing controls. Each one was visible in the Jaloma case, and each one is easy to detect when you know where to look.

Incubation time and temperature

Microbial methods specify minimum incubation times and temperature ranges for a reason. Reading plates early can make a contaminated sample look clean because colonies have not yet grown to a visible size. FDA specifically faulted Jaloma for reading colony counts after less incubation than its own procedure required. Inspectors cross check incubator chart recorders, data loggers and plate reading timestamps against the method. A plate read at hour 30 when the method requires 48 to 72 hours is a finding waiting to happen.

Plate reading and contemporaneous recording

Counts should be recorded at the bench as they are read, by the person who read them, not transcribed later from memory or a scrap of paper. Non contemporaneous recording is one of the most common data integrity citations. A simple control closes most of the gap: record the read directly into a bound logbook or a validated system, and have a second qualified analyst verify counts before the result is reported.

Sampling that was never performed

The most serious Jaloma finding was a microbiologist recording sampling that did not occur. This is fabrication, and FDA treats it as a critical breakdown. Environmental monitoring is especially vulnerable because the sampling happens across a shift and is hard to supervise. Controls include defined sampling schedules tied to room use, independent verification of sample receipt in the laboratory, and reconciliation of plates used against plates logged.

Growth promotion and negative controls

Media that does not support growth will under report contamination, and a missing negative control hides laboratory cross contamination. Every lot of media should pass growth promotion testing before use, and each test run should include the specified positive and negative controls. Inspectors check that growth promotion records exist, that they precede use, and that failures were investigated rather than ignored.

Audit Trails and Computerized Systems in the Micro Lab

Audit trails are the electronic memory of your laboratory. When they are disabled, as they were on the Jaloma gas chromatography system, there is no way to prove that a result was not changed or deleted. 21 CFR 211.68(b) requires controls that ensure only authorized people can create, change or delete electronic records, and that the data is backed up and protected. The same expectation applies to plate readers, automated colony counters, identification systems and the laboratory information management system.

In practice, the quality unit should confirm that:

Audit trails are enabled on every system that generates or stores GMP data, and cannot be switched off by the user.
System clocks are synchronized and users cannot change file creation or modification dates.
Access is role based, with unique logins and no shared accounts, so each action is attributable.
Electronic data is backed up on a defined schedule, and restores are tested.
Audit trail review is part of result review, not a once a year exercise, and the review is documented.

Jaloma could not produce several chromatography data files, timestamps were inaccurate, and nothing was backed up. Any one of these would undermine confidence in a release decision. For a deeper treatment of how inspectors use these records, see our guide to audit trail review as the data integrity battleground.

Method Validation and USP Alignment

A microbial result is only as good as the method behind it. FDA cited Jaloma under 21 CFR 211.160(b) because its alternative microbial methods were not validated against the compendial United States Pharmacopeia methods, the scope omitted tests for anaerobic bacteria and for total yeasts and molds, and incubation times did not align with USP general chapter 61. For non sterile products, USP chapter 61 covers microbial enumeration, USP chapter 62 covers tests for specified microorganisms, and USP chapter 1111 sets acceptance criteria. If you use a rapid or alternative method, you must validate it against the compendial method and justify every difference.

This is a frequent and avoidable failure. Laboratories adopt a faster method, or inherit one from a parent site, and never document the equivalence. When an investigator asks for the validation package and it does not exist, the firm is left admitting, as Jaloma did, that its methods were never validated. Build the validation file before you rely on the method, not after an inspector asks, and align your controls with wider expectations for non sterile microbial contamination control.

The Quality Unit's Responsibility

Under 21 CFR 211.22, the quality unit must have the authority and independence to review records, reject unreliable data and stop product release. FDA found Jaloma's quality unit lacked adequate oversight of both manufacturing and laboratory operations and recommended an executive level review of global operations. A quality unit that reports to production, or that lacks the resources to review audit trails and raw data, is a structural data integrity risk, no matter how good the individual analysts are.

Effective oversight in the microbiology laboratory means independent review of each result against the raw data and audit trail, authority to open a data integrity investigation, and a culture where analysts can escalate pressure to pass a result. When a microbial result is out of specification, it must follow a documented deviation and out of specification investigation procedure rather than being quietly retested until it passes. When FDA finds fabricated data, it almost always asks who in the quality unit should have caught it.

Why This Matters for Canadian Exporters

A microbiology data integrity failure does not stay local. FDA placed Jaloma on Import Alert 66-40, which allows detention without physical examination of its products at the United States border. For a Canadian manufacturer or contract laboratory, the same exposure exists. Health Canada expects the same data integrity standards under its Good Manufacturing Practices Guide (GUI-0001), and findings at a Canadian site can trigger foreign action reporting to other regulators. Micro data that cannot be defended is a direct threat to market access in Canada, the United States and the European Union.

Canadian contract testing laboratories carry particular risk, because a sponsor relies on their certificates of analysis. As we explained in our analysis of the Eurofins contract laboratory warning letter, the sponsor remains accountable for data generated on its behalf. A disciplined supplier and laboratory qualification programme is the difference between knowing your micro data is sound and simply hoping it is.

Microbiology Data Integrity Compliance Checklist

Use this checklist to pressure test your microbiology laboratory before an inspector does.

Every microbial method is validated, including alternative or rapid methods benchmarked against USP chapters 61, 62 and 1111.
Method scope covers all required organisms, including anaerobes and total yeasts and molds where applicable.
Incubation times and temperatures are defined, monitored with calibrated loggers, and enforced against the method.
Plate counts are recorded contemporaneously by the analyst who read them, with second person verification.
Sampling schedules are defined and reconciled, so recorded sampling can be proven to have occurred.
Every media lot passes growth promotion testing before use, with positive and negative controls in each run.
Audit trails are enabled, tamper proof and reviewed as part of result review on every GMP system.
User access is unique and role based, with no shared logins, and system clocks cannot be altered.
Electronic data is backed up on a defined schedule and restores are periodically tested.
Out of specification and out of trend microbial results follow a documented investigation procedure.
The quality unit has the independence and authority to reject data and halt release.
A periodic data integrity self assessment covers the microbiology laboratory, not just the chemistry laboratory.

Common Mistakes

Treating a fabrication finding as one analyst's error instead of a system failure, and disciplining the analyst without fixing the controls.
Validating chemistry systems carefully while leaving plate readers, colony counters and incubators unqualified.
Running alternative microbial methods for years without a documented comparison to the compendial method.
Reviewing results without ever opening the audit trail, so changed or deleted data is never seen.
Allowing shared logins on laboratory systems, which makes every action unattributable.
Reading plates early to keep up with production pressure, then recording the scheduled time.
Responding to a warning letter with a narrow fix instead of the retrospective, independent data review FDA asks for.

Frequently Asked Questions

What is microbiology laboratory data integrity?

It is the assurance that every microbial result is attributable, legible, contemporaneous, original and accurate, and that it can be traced from sample receipt to final report without undocumented change. It applies to enumeration, specified organism tests, sterility, environmental monitoring and identification.

Which regulations did the Jaloma warning letter cite?

FDA cited 21 CFR 211.194(a) for incomplete laboratory records, 211.160(b) for unsound laboratory controls and unvalidated methods, 211.68(b) for inadequate computer and audit trail controls, and 211.22 for a quality unit without adequate oversight. The products were deemed adulterated under section 501(a)(2)(B) of the FD&C Act.

How do inspectors detect microbiology data integrity problems?

They compare incubator and logger records with plate reading times, reconcile plates and media used against what was logged, check whether audit trails are enabled and reviewed, and look for sampling that is recorded but cannot be shown to have happened. They also interview analysts about pressure to pass results.

Do USP chapters apply to Canadian manufacturers?

Health Canada recognizes compendial standards, and products sold in the United States must meet USP requirements. For non sterile products, USP chapters 61, 62 and 1111 are the common reference. If you use an alternative method you must validate it against the compendial method and justify any difference.

What is an import alert and why does it matter?

An import alert lets FDA detain a company's products at the United States border without physically examining each shipment. Jaloma was placed on Import Alert 66-40 in April 2026. Getting off an alert requires evidence that the underlying problems are fixed, which can take many months and independent verification.

How should we respond if we find fabricated micro data?

Treat it as a potential data integrity breach. Secure the records, open a formal investigation, determine the scope across all affected data and products, assess patient risk, and consider an independent third party review. FDA expects a retrospective assessment of all laboratory data, not a single corrected result. If production has already stopped, our restart playbook after an FDA warning letter sets out the sequence regulators expect.

How MFLRC Can Help

MF License and Regulatory Consultants helps pharmaceutical, natural health product and contract testing companies build microbiology laboratories that survive inspection. Our work includes data integrity gap assessments of the microbiology and chemistry laboratories, review and remediation of audit trail and computer system controls, microbial method validation and USP alignment, SOP development for sampling, plate reading and result review, and mock FDA and Health Canada inspections. When a finding has already landed, we help structure the independent retrospective data review and the CAPA that regulators expect, and we coach teams on how to respond to an FDA Form 483 or Health Canada inspection. Our Quality Assurance Person and audit teams bring senior, defensible judgment to high stakes situations.

If your release decisions depend on microbiology results, it is worth knowing whether those results would survive a data integrity inspection. Book a confidential micro lab data integrity review with MFLRC and we will tell you where the gaps are and how to close them.

Book a Micro Lab Data Integrity Review

Conclusion

The Jaloma warning letter is a reminder that microbiology data integrity is built from ordinary controls done consistently: validated methods, honest incubation, contemporaneous recording, working audit trails and a quality unit with real authority. None of these are exotic. All of them are visible to an investigator who knows where to look. Fix the system before the inspection, document it, and your micro data becomes an asset rather than a liability.